Cargando…

Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice

Leucine-rich repeat kinase 2 (LRRK2) is genetically implicated in both familial and sporadic Parkinson's disease (PD). Moreover, LRRK2 has emerged as a compelling therapeutic target for the treatment of PD. Consequently, there is much interest in understanding LRRK2 and its role in PD pathogene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ye, Keshiya, Shikara, Atashrazm, Farzaneh, Gao, Jianqun, Ittner, Lars M., Alessi, Dario R., Halliday, Glenda M., Fu, Yuhong, Dzamko, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academic Press 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197399/ https://www.ncbi.nlm.nih.gov/pubmed/30194047 http://dx.doi.org/10.1016/j.nbd.2018.09.003

Ejemplares similares

Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages
por: Ahmadi Rastegar, Diba, et al.
Publicado: (2022)

Live cell in situ lysosomal GCase activity correlates to alpha-synuclein levels in human differentiated neurons with LRRK2 and GBA1 mutations
por: Labrador-Garrido, Adahir, et al.
Publicado: (2023)

The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling
por: Dzamko, Nicolas, et al.
Publicado: (2012)

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization
por: Dzamko, Nicolas, et al.
Publicado: (2010)

Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites
por: Nirujogi, Raja S., et al.
Publicado: (2021)

LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
por: Atashrazm, Farzaneh, et al.
Publicado: (2016)

Lack of Correlation between the Kinase Activity of LRRK2 Harboring Kinase-Modifying Mutations and Its Phosphorylation at Ser910, 935, and Ser955
por: Ito, Genta, et al.
Publicado: (2014)

Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation
por: Hermanson, Spencer B., et al.
Publicado: (2012)

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts
por: Padmanabhan, Shalini, et al.
Publicado: (2020)

Leucine‐rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes
por: Mercatelli, Daniela, et al.
Publicado: (2019)

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission
por: Qin, Qi, et al.
Publicado: (2016)

Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers
por: Zhao, Ye, et al.
Publicado: (2018)

Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology
por: Dzamko, Nicolas, et al.
Publicado: (2016)

Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms
por: Malik, Asad U., et al.
Publicado: (2021)

Batroxobin inhibits astrocyte activation following nigrostriatal pathway injury
por: Zhang, Zhuo, et al.
Publicado: (2020)

Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
por: Atashrazm, Farzaneh, et al.
Publicado: (2018)

LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease
por: Galper, Jasmin, et al.
Publicado: (2022)

Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases
por: Gomez, Rachel C., et al.
Publicado: (2019)

Early Cognitive Impairment Behind Nigrostriatal Circuit Neurotoxicity: Are Astrocytes Involved?
por: Herrera, Macarena L., et al.
Publicado: (2020)

Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker
por: Perera, G., et al.
Publicado: (2016)

Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2
por: Deng, Xianming, et al.
Publicado: (2011)

Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain
por: Khan, Shahzad S, et al.
Publicado: (2021)

R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations
por: Xenias, Harry S., et al.
Publicado: (2022)

Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease: removing axonal debris
por: Morales, Ingrid, et al.
Publicado: (2021)

Distribution Patterns of Astrocyte Populations in the Human Cortex
por: Forrest, Shelley L., et al.
Publicado: (2022)

A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology
por: Chedid, Jessica, et al.
Publicado: (2022)

Investigation of LKB1 Ser(431) phosphorylation and Cys(433) farnesylation using mouse knockin analysis reveals an unexpected role of prenylation in regulating AMPK activity
por: Houde, Vanessa P., et al.
Publicado: (2014)

LRRK2 Phosphorylation, More Than an Epiphenomenon
por: Marchand, Antoine, et al.
Publicado: (2020)

No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapt(tm1(EGFP)Kit) GFP Knockin Mice
por: van Hummel, Annika, et al.
Publicado: (2016)

Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2
por: Waschbüsch, Dieter, et al.
Publicado: (2020)

9,10-Dimethyl-9,10-peroxy-9,10-dihydroanthracene
por: Wang, Yun-Wu
Publicado: (2008)

Parkinson’s disease-implicated kinases in the brain; insights into disease pathogenesis
por: Dzamko, Nicolas, et al.
Publicado: (2014)

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
por: Nichols, R. Jeremy, et al.
Publicado: (2010)

‘Up with the LRRK’: a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagement
por: Eyers, Patrick A.
Publicado: (2016)

Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis
por: Steger, Martin, et al.
Publicado: (2017)

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation
por: Kawakami, Fumitaka, et al.
Publicado: (2015)

POS-935 OUTCOME OF COVID-19 IN DIALYSIS PATIENTS IN KELANTAN
por: Fakri, A., et al.
Publicado: (2022)

Accurate MS-based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson's Disease
por: Karayel, Özge, et al.
Publicado: (2020)

LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models
por: Guerreiro, Patrícia Silva, et al.
Publicado: (2012)

Parkinson’s progression prediction using machine learning and serum cytokines
por: Ahmadi Rastegar, Diba, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ikin5jsbe1d8ip78tlt2hl0ve3